Catalent, Inc. Reports First Quarter Fiscal Year 2017 Results

• Q1’17 revenue $442.2 million increased 5% as-reported, or 7% in
  constant currency from the prior year period.
• Acquired Pharmatek Laboratories, a West Coast, U.S.-based
  specialist in drug development and clinical manufacturing; adds
  extensive formulation and development capabilities.
• Triphase Accelerator has obtained worldwide rights to an
  oncology treatment developed using Catalent’s proprietary SMARTag
  technology.
• Reached an agreement with Moderna Therapeutics to support
  near-term Good Manufacturing Practice (GMP) efforts for Phase 1/2
  clinical studies for its personalized cancer vaccines.

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced financial results for the
first quarter of fiscal year 2017, which ended September 30, 2016.

First quarter 2017 revenue of $442.2 million increased 5% as reported
and increased 7% in constant currency from $423.0 million reported in
the first quarter a year ago. All three of the Company’s reporting
segments posted constant currency revenue growth for the first quarter,
led by a double-digit increase in the Drug Delivery Solutions segment.

First quarter 2017 net earnings attributable to Catalent were $4.6
million, or $0.04 per diluted share, compared to net earnings of $11.9
million, or $0.09 per diluted share, in the first quarter a year ago.

First quarter 2017 EBITDA from continuing operations of $62.7 million
decreased 13% from $72.1 million in the first quarter a year ago.

First quarter 2017 Adjusted EBITDA, as referenced in the GAAP to
non-GAAP reconciliation provided later in this release, was $75.0
million, or 17.0% of revenue, compared to $77.6 million, or 18.3% of
revenue, in the first quarter a year ago. This represents an increase of
3% on a constant currency basis.

First quarter 2017 Adjusted Net Income, as referenced in the GAAP to
non-GAAP reconciliation provided later in this release, was $19.6
million, or $0.16 per diluted share, compared to Adjusted Net Income of
$23.0 million, or $0.18 per diluted share, in the first quarter a year
ago.

“We’re pleased to start fiscal year 2017 with strong revenue growth, the
completion of a strategic acquisition, and several exciting developments
on the Biologics front,” said John Chiminski, President and Chief
Executive Officer of Catalent, Inc. “The acquisition of Pharmatek adds
extensive early-phase drug development capabilities from discovery to
clinic and brings spray drying technology into Catalent’s extensive
portfolio of advanced delivery technologies. The Biologics project wins
this quarter highlight our differentiated technology platforms in this
space in support of our customers and patients.”

First Quarter 2017 Segment Highlights

Revenue Highlights by Business Segment

Revenue from the Softgel Technologies segment was $186.4 million for the
first quarter of fiscal 2017, an increase of 1% as reported, or 2% in
constant currency, compared to the first quarter a year ago. The
constant currency growth was attributable to higher end-market volume
demand for consumer health products, primarily in Latin America and Asia
Pacific; partially offset by lower volume at our Beinheim facility as
compared to pre-suspension levels of production during the first quarter
of the prior fiscal year.

Revenue from the Drug Delivery Solutions segment was $191.3 million for
the first quarter of fiscal 2017, an increase of 10% as reported, or 13%
in constant currency, over the first quarter a year ago. The strong
performance was primarily driven by volumes related to fee-for-service
development and analytical testing in the U.S., and strength within our
biologics offering and our European pre-filled syringe operations. This
growth was partially offset by decreased volume in our integrated oral
solids development and manufacturing capabilities.

Revenue from the Clinical Supply Services segment was $75.0 million for
the first quarter of fiscal 2017, a decrease of 3% as reported, or an
increase of 3% in constant currency over the first quarter a year ago.
This growth was primarily due to increased volume related to core
storage and distribution activities.

Segment EBITDA Highlights

Softgel Technologies segment EBITDA in the first quarter of 2017 was
$30.5 million, a decrease of 12% as reported, or 7% in constant
currency, versus the first quarter a year ago. The decrease was
primarily attributable to lower volume at our Beinheim facility as
compared to pre-suspension levels of production in the first quarter of
the prior fiscal year; partially offset by increased volume and higher
capacity utilization within Latin America.

Drug Delivery Solutions segment EBITDA in the first quarter of 2017 was
$42.0 million, an increase of 12% as reported, or 18% in constant
currency. The increase was primarily driven by increased volumes and
favorable product mix within our analytical services platform and our
biologics offering, partially offset by decreased volumes and
unfavorable product mix within our integrated oral solids development
and manufacturing capabilities.

Clinical Supply Services segment EBITDA in the first quarter of 2017 was
$10.5 million, a decrease of 25% as reported, or 17% in constant
currency. The decrease was primarily attributable to an unfavorable
service offering revenue mix to our lower margin storage and
distribution business from our higher margin manufacturing and packaging
business, as well as due to higher costs across the segment.

Additional Financial Highlights

First quarter 2017 gross margin of 28.1% declined 60 basis points
as-reported, or 10 basis points in constant currency, from 28.7% in the
first quarter a year ago. The decrease was primarily attributable to
unfavorable revenue mix within our Clinical Supply Services segment
during the first quarter of the current fiscal year, partially offset by
favorable product mix within the Drug Delivery Solutions segment.

First quarter 2017 selling, general and administrative expenses were
$98.2 million and represented 22.2% of revenue, compared to $82.3
million, or 19.5% of revenue, in the first quarter a year ago. The
increase in the current year was primarily driven by higher employee
related costs resulting from inflationary increases, employee retention
and recruiting, health and wellness expense, and non-cash equity-based
compensation plans.

Backlog for the Clinical Supply Services segment, defined as estimated
future service revenues from work not yet completed under signed
contracts was $308.6 million as of September 30, 2016, a 6% increase
compared to the fourth quarter of fiscal year 2016. The segment also
recorded net new business wins of $92.2 million during the first
quarter, which represented a 6% increase year over year. The segment’s
trailing-twelve-month book-to-bill ratio was 1.2x.

Balance Sheet and Liquidity

As of September 30, 2016, Catalent had $1.9 billion in total debt, and
$1.8 billion in total debt net of cash and short term investments, which
is modestly above the total and net debt levels as of June 30, 2016 due
to the acquisition of Pharmatek. As of September 30, 2016, Catalent’s
net leverage ratio was 4.5x, compared to 4.3x as of June 30, 2016. This
quarter’s net leverage ratio proforma for the acquisition of Pharmatek
was 4.4x.

Fiscal Year 2017 Outlook

There is no change to Catalent’s previously issued financial guidance.
For fiscal year 2017, the company expects revenue in the range of $1.920
billion to $1.995 billion. Catalent expects Adjusted EBITDA in the range
of $430 million to $455 million and Adjusted Net Income in the range of
$165 million to $190 million. These guidance ranges are consistent with
the organic, constant currency long-term CAGR growth expectations of
4-6% for revenue and 6-8% for Adjusted EBITDA. The Company expects
self-funded capital expenditures in the range of $125 million to $135
million and fully diluted share count in the range of 126 million to 128
million shares on a weighted average basis.

Earnings Webcast

The Company’s management will host a webcast to discuss the results at
4:45 p.m. ET today. Catalent invites all interested parties to listen to
the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com.
A supplemental slide presentation will also be available in the
“Investors” section of Catalent’s website prior to the start of the
webcast. The webcast replay, along with the supplemental slides, will be
available for 90 days in the “Investors” section of Catalent’s website
at www.catalent.com.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs approximately
9,500 people, including over 1,400 scientists, at more than 30
facilities across 5 continents and in fiscal 2016 generated $1.85
billion in annual revenue. Catalent is headquartered in Somerset, N.J.
For more information, please visit www.catalent.com.

Non-GAAP Financial Measures

Use of EBITDA from continuing operations, Adjusted EBITDA, Adjusted
Net Income and Segment EBITDA

Management measures operating performance based on consolidated earnings
from continuing operations before interest expense, expense/(benefit)
for income taxes, and depreciation and amortization, and it is adjusted
for the income or loss attributable to non-controlling interest (“EBITDA
from continuing operations”). EBITDA from continuing operations is not
defined under U.S. GAAP and is not a measure of operating income,
operating performance or liquidity presented in accordance with U.S.
GAAP and is subject to important limitations.

The Company believes that the presentation of EBITDA from continuing
operations enhances an investor’s understanding of its financial
performance. The Company believes this measure is a useful financial
metric to assess its operating performance from period to period by
excluding certain items that it believes are not representative of its
core business and uses this measure for business planning purposes.

In addition, given the significant investments that Catalent has made in
the past in property, plant and equipment, depreciation and amortization
expenses represent a meaningful portion of its cost structure. The
Company believes that EBITDA from continuing operations will provide
investors with a useful tool for assessing the comparability between
periods of its ability to generate cash from operations sufficient to
pay taxes, to service debt and to undertake capital expenditures because
it eliminates depreciation and amortization expense. The Company
presents EBITDA from continuing operations in order to provide
supplemental information that it considers relevant for the readers of
the Consolidated Financial Statements, and such information is not meant
to replace or supersede U.S. GAAP measures. The Company’s definition of
EBITDA from continuing operations may not be the same as similarly
titled measures used by other companies.

Catalent evaluates the performance of its segments based on segment
earnings before non-controlling interest, other (income)/expense,
impairments, restructuring costs, interest expense, income tax
expense/(benefit), and depreciation and amortization (“segment EBITDA”).
Moreover, under the Company’s credit agreement, its ability to engage in
certain activities, such as incurring certain additional indebtedness,
making certain investments and paying certain dividends, is tied to
ratios based on Adjusted EBITDA, which is not defined under U.S. GAAP
and is subject to important limitations. Adjusted EBITDA is the covenant
compliance measure used in the credit agreement governing debt
incurrence and restricted payments. Because not all companies use
identical calculations, the Company’s presentation of Adjusted EBITDA
may not be comparable to other similarly titled measures of other
companies.

Management also measures operating performance based on Adjusted Net
Income/(loss). Adjusted Net Income/(loss) is not defined under U.S. GAAP
and is not a measure of operating income, operating performance or
liquidity presented in accordance with U.S. GAAP and is subject to
important limitations. The Company believes that the presentation of
Adjusted Net Income/(loss) enhances an investor’s understanding of its
financial performance. The Company believes this measure is a useful
financial metric to assess its operating performance from period to
period by excluding certain items that it believes are not
representative of its core business and the Company uses this measure
for business planning purposes. The Company defines Adjusted Net
Income/(loss) as net earnings/(loss) adjusted for (1) earnings or loss
of discontinued operations, net of tax (2) amortization attributable to
purchase accounting and (3) income or loss from non-controlling interest
in its majority-owned operations. The Company also makes adjustments for
other cash and non-cash items included in the table below, partially
offset by its estimate of the tax effects as a result of such cash and
non-cash items. The Company believes that Adjusted Net Income/(loss)
will provide investors with a useful tool for assessing the
comparability between periods of its ability to generate cash from
operations available to its stockholders. The Company’s definition of
Adjusted Net Income/(loss) may not be the same as similarly titled
measures used by other companies.

The most directly comparable GAAP measure to EBITDA from continuing
operations and Adjusted EBITDA is earnings/(loss) from continuing
operations. The most directly comparable GAAP measure to Adjusted Net
Income/(loss) is net earnings/(loss). Included in this release is a
reconciliation of earnings/(loss) from continuing operations to EBITDA
from continuing operations and Adjusted EBITDA and reconciliation of net
earnings/(loss) to Adjusted Net Income.

The Company does not provide a reconciliation of forward-looking
non-GAAP financial measures to their comparable GAAP financial measures
because it could not do so without unreasonable effort due to the
unavailability of the information needed to calculate reconciling items
and due to the variability, complexity and limited visibility of the
adjusting items that would be excluded from the non-GAAP financial
measures in future periods. When planning, forecasting and analyzing
future periods, the Company does so primarily on a non-GAAP basis
without preparing a GAAP analysis as that would require estimates for
various cash and non-cash reconciling items that would be difficult to
predict with reasonable accuracy. For example, equity compensation
expense would be difficult to estimate because it depends on the
Company’s future hiring and retention needs, as well as the future fair
market value of the Company’s common stock, all of which are difficult
to predict and subject to constant change. It is equally difficult to
anticipate the need for or magnitude of a presently unforeseen one-time
restructuring expense or the values of end-of-period foreign currency
exchange rates. As a result, the Company does not believe that a GAAP
reconciliation would provide meaningful supplemental information about
the Company’s outlook.

Use of Constant Currency

As changes in exchange rates are an important factor in understanding
period-to-period comparisons, the Company believes the presentation of
results on a constant currency basis in addition to reported results
helps improve investors’ ability to understand its operating results and
evaluate its performance in comparison to prior periods. Constant
currency information compares results between periods as if exchange
rates had remained constant period over period. The Company uses results
on a constant currency basis as one measure to evaluate its performance.
The Company calculates constant currency by calculating current-year
results using prior-year foreign currency exchange rates. The Company
generally refers to such amounts calculated on a constant currency basis
as excluding the impact of foreign exchange or being on a constant
currency basis. These results should be considered in addition to, not
as a substitute for, results reported in accordance with U.S. GAAP.
Results on a constant currency basis, as the Company presents them, may
not be comparable to similarly titled measures used by other companies
and are not measures of performance presented in accordance with U.S.
GAAP.

Forward-Looking Statements

This release contains both historical and forward-looking statements.
All statements other than statements of historical fact are, or may be
deemed to be, forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements generally can be identified by the use of statements that
include phrases such as “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,”
“would” or other words or phrases with similar meanings. Similarly,
statements that describe the Company’s objectives, plans or goals are,
or may be, forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from Catalent, Inc.’s expectations and
projections. Some of the factors that could cause actual results to
differ include, but are not limited to, the following: participation in
a highly competitive market and increased competition may adversely
affect the business of the Company; demand for the Company’s offerings
which depends in part on the Company’s customers’ research and
development and the clinical and market success of their products;
product and other liability risks that could adversely affect the
Company’s results of operations, financial condition, liquidity and cash
flows; failure to comply with existing and future regulatory
requirements; failure to provide quality offerings to customers could
have an adverse effect on the Company’s business and subject it to
regulatory actions and costly litigation; problems providing the highly
exacting and complex services or support required; global economic,
political and regulatory risks to the operations of the Company;
inability to enhance existing or introduce new technology or service
offerings in a timely manner; inadequate patents, copyrights, trademarks
and other forms of intellectual property protections; fluctuations in
the costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials; changes
in market access or healthcare reimbursement in the United States or
internationally; fluctuations in the exchange rate of the U.S. dollar
and other foreign currencies including as a result of the recent U.K.
referendum to exit from the European Union; adverse tax legislation
initiatives or challenges to the Company’s tax positions; loss of key
personnel; risks generally associated with information systems;
inability to complete any future acquisitions and other transactions
that may complement or expand the business of the Company or divest of
non-strategic businesses or assets and the Company’s ability to
successfully integrate acquired business and realize anticipated
benefits of such acquisitions; offerings and customers’ products that
may infringe on the intellectual property rights of third parties;
environmental, health and safety laws and regulations, which could
increase costs and restrict operations; labor and employment laws and
regulations; additional cash contributions required to fund the
Company’s existing pension plans; substantial leverage resulting in the
limited ability of the Company to raise additional capital to fund
operations and react to changes in the economy or in the industry,
exposure to interest rate risk to the extent of the Company’s variable
rate debt and preventing the Company from meeting its obligations under
its indebtedness. For a more detailed discussion of these and other
factors, see the information under the caption “Risk Factors” in the
Company’s Annual Report on Form 10-K for the fiscal year ended June 30,
2016, filed with the Securities and Exchange Commission. All
forward-looking statements speak only as of the date of this release or
as of the date they are made, and Catalent, Inc. does not undertake to
update any forward-looking statement as a result of new information or
future events or developments except to the extent required by law.

More products. Better treatments. Reliably supplied.™

Contacts

Investor:
Catalent, Inc.
Thomas Castellano, 732-537-6325
investors@catalent.com

Read full story here